🔗 Share this article

While the United States proceeds with sweeping adjustments to its vaccination recommendations, a particular individual has surfaced somewhat surprisingly: Høeg, a Danish American physician and public health researcher who rose to prominence by expressing skepticism about COVID-19 vaccines in the pandemic and has zeroed in on alleged fatalities after Covid immunization in her recent tenure at the Food and Drug Administration.

Scheduled Changes to Childhood Vaccine Schedule

Health officials had intended to unveil sweeping revisions to the childhood vaccination calendar in December, synchronizing the US with Denmark’s national calendar, sources say – a substantial departure that would place the US out of step with much of the international standard with no evidence for public health gain. This reveal has been delayed until the new year.

In place of the director of the vaccine center, Tracy Beth Høeg is set to speak at the gathering. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the center this year.

A New Direction at the Regulatory Body

The acting appointment might represent a tighter collaboration between the drug and vaccine divisions as Dr. Høeg and Dr. Prasad solidify control at the FDA – and it signals a renewed priority upon reevaluating previously authorized immunizations at the FDA.

Dr. Høeg has repeatedly called for ending some childhood vaccine recommendations in the US to become more in line with Denmark, a society with nationalized medicine and a citizenry approximately the size of the state of Wisconsin.

To date public appearances, she has kept her attention on vaccines – usually the domain of Dr. Prasad, chief of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Doubts Over Expertise

Dr. Høeg has no apparent experience in pharmaceutical research, regulation or management, which has been typical for past leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the commissioner and the vaccine center since earlier this year.

“She doesn’t seem to have any of the qualifications” for leading the pharmaceutical oversight division, said Dr. Jonathan Howard. “She has not conducted a scientific study. She is not versed in leading a sizeable institution. She has no expertise in drug approvals.”

Past commissioners of CBER would “be deeply familiar with regulatory frameworks and the research of pharmaceutical innovation”, noted a former acting FDA commissioner. “Objectively, she has not acquired the type of experience that prior appointees who headed the center have had.”

The drug center has an immense portfolio at the agency, the former commissioner emphasized.

“The public just pays attention on the innovative therapies, but the generic drug division clears a multitude of generic medications. There’s a biosimilars program, over-the-counter program and so forth, and all of those need to be looked after,” Dr. Woodcock noted. “The responsibility you neglect, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a significant management element to the role, which supervises more than 5,000 employees. “It is a huge administrative position, if you do it right,” she added.

Response and Disputed Programs

When asked about questions about Dr. Høeg's qualifications and whether this selection represents greater collaboration among agency officials on immunizations, a press secretary stated that the “inquiries rely on flawed assumptions”.

“Her experience aligns with the responsibilities of her position,” the spokesperson stated, citing the period Høeg spent guiding the FDA commissioner on “pharmaceutical safety and regulatory science, including computational safety modeling and vaccine surveillance”.

As acting director, Dr. Høeg takes over the agency head's new priority voucher program, a disputed rapid therapy clearance system that apparently troubled her former heads. “By what process are these medications being selected for this fast-track system? Who makes the choices?” Howard asked. “There is a lot of lack of transparency occurring at the FDA right now.”

Overall, he said, “the FDA appears to be shifting towards less stringent regulations of all drugs, with the exception of immunizations.”

Established Past Work on Immunizations

With vaccines, Dr. Høeg has a more documented, if concerning, history, Howard have noted. She published a analysis using unverified public submissions to assess the rate of myocarditis after COVID-19 vaccination. She counseled the Florida top health official Dr. Joseph Ladapo, who reportedly have altered data to indicate COVID-19 vaccinations are pose a greater threat than they are.

Included in her “desired changes” for the incoming administration featured altering regulations for new vaccines and ending “non-essential” immunizations, she remarked following the vote on a online show. At the agency, Høeg has allegedly proposed preventing young men from getting Covid vaccinations.

“She is an all-around ideologue who begins with her preconceived notions and reverse-engineers to accommodate the evidence in a extremely misleading, fraudulent way,” Dr. Howard argued.

Gaining Influence and a “Revenge Tour”

Høeg became part of other dissenters, {like|